the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Clinical trial evaluating the efficacy and safety of salbutamol for the treatment of neonates with a gestational age between 32 and 42 weeks with transient tachypnoea of the newborn (TTN).
Epistemonikos ID: 981c5a3bf50d21ea92638dc846f64920ede183d3
First added on: May 13, 2024